Clinical Observation Of Modified Renshensini Decoction Combined With Entresto In The Treatment Of Chronic Heart Failure With Heart Yang Deficiency Type

Objective:To observe the clinical effect of modified Renshensini decoction combined with Entresto on NYHA cardiac function grade,6-minute walking test,NT-proBNP,LVEF,and TCM syndrome scores in patients with chronic heart failure with heart yang deficiency type,to evaluate the clinical symptoms,improvement of quality of life and clinical safety,to provide a new clinical reference and method for the future treatment of patients with chronic heart failure.Methods:A total of 60 patients with chronic heart failure who were selected inclusion criteria from outpatient department of this hospital from January 2022 to December 2022,and they were randomly divided into 30 cases of test group and control group according to the random number table method.The control group was treated with basic western medicine and Entresto,the test group was additionally modified Renshensini decoction,with 4 weeks as the observation period.During this period,clinical symptoms,NYHA cardiac function grade,6-minute walking test,NT-proBNP,LVEF and TCM symptom scores were observed and recorded.The obtained data were processed and analyzed using the statistical software SPSS26.0.Results:1.Comparison of general data:Between the test and control groups,there were no significant difference in age,sex and underlying disease conditions(P>0.05),which were comparable.2.Comparison of NYHA cardiac function grade:After treatment,the cardiac function in both groups improved compared with before treatment(P<0.05),and the total effective rate of the control group was 62.07%,and the test group was 86.21%.3.Comparison of 6-minute walking test:After treatment,the walking distance in both groups were prolonged compared with before treatment(P<0.05),and the distance extension of the test group was more significant than the control group.4.Comparison of NT-proBNP:After treatment,the NT-proBNP level in both groups were decreased compared with before treatment(P<0.05),which was more significant in the test group.5.Comparision of LVEF:After treatment,the LVEF in both groups were increased compared with before treatment,and the difference was significant(P<0.05),and the degree of increase in the test group was higher than the control group.6.Comparision of TCM syndrome scores:After treatment,the TCM syndrome scores of the two groups have decreased compared with before treatment,with the degree of decrease in the test group was more significant than that of the control group(P<0.05),the total effective rate of TCM syndrome efficacy was 79.31%(control group)and89.65%(test group),the test group was better in improving TCM systemic symptoms than control group.7.Adverse reactions:The safety indexes of patients in both groups were normal during the whole treatment,and no serious adverse reactions occurred,and the safety was better.Conclusion:1.The modified Renshensini decoction combined with Entresto can improve the cardiac function,prolong the 6-minute walking distance,reduce the serum NT-proBNP level,improve the LVEF of chronic heart failure with heart yang deficiency type,and slow down the process of heart failure.2.The modified Renshensini decoction combined with Entresto can reduce the level of TCM individual syndrome scores and total scores in patients of chronic heart failure with heart yang deficiency type,and significantly improved the clinical symptoms of patients.